Seeking Alpha

CytRx reports positive top-line data from aldoxorubicin STS trial

  • CytRx (CYTR) is out with top-line results from a Phase 2b study of aldoxorubicin in first-line metastatic, locally advanced or unresectable STSs.
  • Summary (intent-to-treat analysis): Median PFS for aldoxorubicin, 8.4 months; median PFS for doxorubicin, 4.7 months.
  • Summary (blinded central lab review): Median PFS for aldoxorubicin, 5.7 months; median PFS for doxorubicin, 2.8 months.
  • OR rate: 25.4% for aldoxorubicin, 5.4% for doxorubicin.
  • "These results are extraordinary for a single agent treating these chemotherapy-resistant tumors," the study's principal investigator says. (PR)
  • CYTR +32% premarket.
Comments (2)
  • 487371
    , contributor
    Comments (13) | Send Message
    remarkable what effect on share price results from a barely significant clinical effect for any cancer therapy! Does anyone remember DNDN? SRPT is another one with insignificant data (but it took a long time for the FDA to figure that one out.
    11 Dec 2013, 09:33 AM Reply Like
  • Biomaster
    , contributor
    Comments (216) | Send Message
    STRONG clinical effect was results of this trial-
    So what are you talking about?
    Standard of care is very poor in this patient population-
    ANY improvement is significant.
    11 Dec 2013, 10:08 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: